Baird Maintains Neutral on Edwards Lifesciences, Raises Price Target to $87

Benzinga Newsdesk www.benzinga.com Neutral 59.4%

Neg 0% Neu 59.4% Pos 0%

Baird analyst David Rescott maintains Edwards Lifesciences (NYSE:EW) with a Neutral and raises the price target from $85 to $87.